$9.61
3.89% yesterday
Nasdaq, Sep 27, 10:16 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock price

$9.61
-1.79 15.70% 1M
-4.49 31.84% 6M
+1.48 18.20% YTD
+5.11 113.56% 1Y
-15.69 62.02% 3Y
-8.38 46.58% 5Y
+2.61 37.29% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.36 3.89%
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Key metrics

Market capitalization $2.81b
Enterprise Value $2.48b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 75.57
P/S ratio (TTM) P/S ratio 85.67
P/B ratio (TTM) P/B ratio 3.58
Revenue growth (TTM) Revenue growth 13,669.75%
Revenue (TTM) Revenue $32.77m
EBIT (operating result TTM) EBIT $-459.25m
Free Cash Flow (TTM) Free Cash Flow $-400.48m
Cash position $412.62m
EPS (TTM) EPS $-1.68
P/E forward negative
P/S forward 17.31
EV/Sales forward 15.27
Short interest 21.97%
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Iovance Biotherapeutics Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
33 33
13,554% 13,554%
100%
- Direct Costs 74 74
200% 200%
225%
-41 -41
68% 68%
-125%
- Selling and Administrative Expenses 61 61
7% 7%
187%
- Research and Development Expense 317 317
2% 2%
967%
-419 -419
4% 4%
-1,278%
- Depreciation and Amortization 40 40
65% 65%
123%
EBIT (Operating Income) EBIT -459 -459
7% 7%
-1,401%
Net Profit -440 -440
5% 5%
-1,343%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Positive
The Motley Fool
one day ago
Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.
Positive
The Motley Fool
12 days ago
Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.
Neutral
The Motley Fool
21 days ago
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 557
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today